DATA - The Buzz Show: Intellia Therapeutics Inc. (NASDAQ: NTLA) Positive Gene Editing Data

FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Intellia Therapeutics, Inc. Surges Following Positive Gene Editing Data ”

Intellia Therapeutics, Inc. (NASDAQ: NTLA) surged over 59% in premarket trading after the Company and Regeneron Pharmaceuticals announced positive interim data from an ongoing Phase 1 clinical study of their lead in vivo genome editing candidate, NTLA-2001.

The Phase 1 study of a single-dose treatment for ATTR is evaluating the first CRISPR/Cas9-based therapy candidate to be administered systemically, via intravenous infusion, for precision editing of a gene in a target tissue in humans.

Intellia Therapeutics, a leading clinical-stage genome editing company, is developing novel, potentially curative therapeutics using CRISPR/Cas9 technology. To fully realize the transformative potential of CRISPR/Cas9, Intellia is pursuing two primary approaches. The company’s in vivo programs use intravenously administered CRISPR as the therapy, in which proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia’s ex vivo programs use CRISPR to create the therapy by removing, re-engineering and re-infusing the patient’s own cells to treat cancer and autoimmune diseases. Intellia’s deep scientific, technical and clinical development experience, along with its robust intellectual property portfolio, have enabled the company to take a leadership role in harnessing the full potential of CRISPR/Cas9 to create new classes of genetic medicine.

For more information, please visit: Intellia Therapeutics, Inc.

About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.

The post “The Buzz” Show: Intellia Therapeutics, Inc. (NASDAQ: NTLA) Positive Gene Editing Data first appeared on Financial Buzz .

For further details see: